Among antidementia drugs, memantine is associated with the highest risk of pneumonia
A recent study from the University of Eastern Finland shows that among users of antidementia drugs, persons using memantine have the highest risk of pneumonia. The use of rivastigmine patches is associated with an increased risk as well. The study found that persons using donepezil or galantamine had the lowest risk of pneumonia. (Source: World Pharma News)
Source: World Pharma News - November 25, 2016 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Another Failure In Search For Treatment To Slow Alzheimer ’ s
INDIANAPOLIS (AP) — An experimental treatment for Alzheimer’s failed again in a widely anticipated study, disappointing many who had hoped Eli Lilly had finally found a way to slow the progression of the mind-robbing disease.
The drug did not work better than a placebo treatment in a study of 2,100 people with mild Alzheimer’s, the company announced Wednesday.
“We’re incredibly saddened by the news,” said Maria Carrillo, chief science officer of the Alzheimer’s Association, who was not involved in Lilly’s research. “There was a lot of hope for this avenue, this approach....
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 23, 2016 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Local News Alzheimer's Disease Solanezumab Source Type: news
Among antidementia drugs, memantine is associated with the highest risk of pneumonia
Among users of antidementia drugs, persons using memantine have the highest risk of pneumonia, new research shows. The use of rivastigmine patches is associated with an increased risk as well, say researchers. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 21, 2016 Category: Science Source Type: news
FDA approves Lannett's generic dementia drug
The Food and Drug Administration has approved Lannett Co. Inc. ’s application to market memantine hydrochloride tablets for the treatment of dementia.
The product is the generic equivalent of Namenda, a medicine developed by Forest Laboratories to treat moderate-to-severe dementia in patients, including those suffering from Alzheimer’s disease.
Dr. Reddy’ s Laboratories and Mylan were the first to introduce generic versions of Namenda last year. Teva Pharmaceutical Industries (NYSE: TEVA),… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 14, 2016 Category: Biotechnology Authors: John George Source Type: news
Allergan Issues Statement on Namenda XR Patent Litigation Following Announcement of ANDA Approvals
DUBLIN, Sept. 29, 2016 -- (Healthcare Sales & Marketing Network) -- Allergan plc (AGN), today issued the following statement regarding ongoing litigation on patents related to NAMENDA XR® (memantine hydrochloride) extended release capsules following a... Biopharmaceuticals, Generics, FDA, Litigation Allergan, NAMENDA, memantine, Lupin Pharmaceuticals (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 29, 2016 Category: Pharmaceuticals Source Type: news
Treatment of Alzheimer ’ s Disease
There is no cure for Alzheimer’s disease and no way to slow the progression of the disease. For some people in the early or middle stages of Alzheimer’s disease, medication such as tacrine (Cognex) may alleviate some cognitive symptoms. Donepezil (Aricept), rivastigmine (Exelon), and galantamine (Reminyl) may keep some symptoms from becoming worse for a limited time. A fifth drug, memantine (Namenda), has also been approved for use in the United States.
Combining memantine with other Alzheimer’s disease drugs may be more effective than any single therapy. One controlled clinical trial found that patients...
Source: Psych Central - August 17, 2016 Category: Psychiatry Authors: Jane Framingham, Ph.D. Tags: Alzheimer's Medications Memory and Perception Alzheimer's treatment Cognex donepezil Drug Exelon galanta Namenda Reminyl rivastigmine tacrine treatment of alzheimers Source Type: news
Clinical Trials For New Alzheimer's Medication
Inside Science News Servicenoted on April 16, 2016 that "Alzheimer's is a graveyard for expensive drug tests. One study showed that between 2000 and 2012, 244 compounds were tested in 413 clinical trials. Only one was approved for use, a failure rate of 99.6 percent."
The one medication that was approved since the year 2000, Namzeric, is a medication that combines two previously FDA-approved medications, donepezil and memantine, into one capsule. But neither donepezil nor memantine are medications that effectively treat or significantly improve the lives of most people who take them. Even the third sentence on the N...
Source: Healthy Living - The Huffington Post - July 19, 2016 Category: Consumer Health News Source Type: news
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease
This guidance updates and replaces NICE technology appraisal guidance 111 issued in November 2006 (amended September 2007, August 2009).
The review and re-appraisal of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer ' s disease has resulted in a change in the guidance.
Specifically:
donepezil, galantamine and rivastigmine are now recommended as options for managing mild as well as moderate Alzheimer ' s disease, and
memantine is now recommended as an option for managing moderate Alzheimer ' s disease for people who cannot take AChE inhibitors, and as an option for managing sev...
Source: Current Awareness Service for Health (CASH) - July 12, 2016 Category: Consumer Health News Source Type: news
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease
This guidance updates and replaces NICE technology appraisal guidance 111 issued in November 2006 (amended September 2007, August 2009).
The review and re-appraisal of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease has resulted in a change in the guidance.
Specifically:
donepezil, galantamine and rivastigmine are now recommended as options for managing mild as well as moderate Alzheimer's disease, and
memantine is now recommended as an option for managing moderate Alzheimer's disease for people who cannot take AChE inhibitors, and as an option for managing severe Alzhei...
Source: Current Awareness Service for Health (CASH) - July 12, 2016 Category: Consumer Health News Source Type: news
memantine, Namenda, Namenda XR
Title: memantine, Namenda, Namenda XRCategory: MedicationsCreated: 11/3/2003 12:00:00 AMLast Editorial Review: 6/20/2016 12:00:00 AM (Source: MedicineNet Alzheimer)
Source: MedicineNet Alzheimer - June 20, 2016 Category: Geriatrics Source Type: news
Characteristics of pediatric exposures to antidementia drugs reported to a poison control system - Thornton SL, Pchelnikova JL, Cantrell FL.
OBJECTIVE: To characterize pediatric exposures to the antidementia drugs donepezil, memantine, rivastigmine, and galantamine by reviewing a poison control system's database. STUDY DESIGN: A retrospective review of a statewide poison control system's databa... (Source: SafetyLit)
Source: SafetyLit - March 11, 2016 Category: Global & Universal Tags: Age: Infants and Children Source Type: news
Memantine Hydrochloride (Namenda) Unit Dose XR Capsules (New - Discontinuation)
Updated Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - February 17, 2016 Category: Drugs & Pharmacology Source Type: news
Memantine Hydrochloride (Namenda) XR Capsules (Updated - Resolved)
Updated Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - February 3, 2016 Category: Drugs & Pharmacology Source Type: news
Pfizer-Allergan deal a prelude to splitting company
(Reuters) — A Pfizer (NYSE:PFE) merger with Ireland-based Allergan (NYSE: AGN), in addition to providing tax benefits, would bolster the U.S. drugmaker’s growth prospects should it decide to sell or spin off its portfolio of products that have gone off patent.
Many Wall Street analysts believe Pfizer will decide to split late next year, after compiling 3 years of financial data treating its “established products” division, which sells generic medicines, and its “innovative” patent-protected medicines unit, as if they were separate companies.
Such a split would dramatically boost the compan...
Source: Mass Device - November 6, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Mergers & Acquisitions Pharmaceuticals Allergan Inc. Pfizer Inc. Source Type: news
Cheap Alzheimer's drug 'may help keep people out of care homes'
Conclusion
This randomised controlled trial assessed the impact of continuing or discontinuing the Alzheimer's drug donepezil on the chances of nursing home admission in people with moderate to severe Alzheimer's.
The study examined discontinuing or continuing donepezil, either alone or in combination with memantine, or switching to memantine alone. Memantine is currently licensed for the treatment of moderate to severe Alzheimer's, while donepezil is only licensed for mild to moderate forms of the disease.
In this trial, people had already been taking donepezil for three to six months or more. These drugs are only given...
Source: NHS News Feed - October 27, 2015 Category: Consumer Health News Tags: Medication Mental health Neurology Older people Source Type: news
